Zhitong Finance App News, China Biopharmaceutical (01177) issued an announcement. The group will announce 21 latest research results at the 2026 Chinese Society of Clinical Oncology (CSCO) Academic Annual Meeting, including 5 oral reports. The research involved the research project TQB3454 (IDH1 inhibitor), as well as the marketed product anlotinib capsule (trade name: fukowil®), bemosubizumab injection (trade name: Andevil®), abergestine alpha injection (trade name: Ellisshu®), and piamprizumab injection (trade name: Anicol®), covering various treatment fields such as pancreatic cancer, lung cancer, renal cell carcinoma, gastrointestinal tumors, soft tissue sarcoma, thyroid cancer, and breast cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.